These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

905 related items for PubMed ID: 23265714

  • 21. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T, Yokota S, Nakao M, Misawa S, Takaue Y, Koizumi S, Kawai S, Fujimoto T.
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [Abstract] [Full Text] [Related]

  • 22. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A, Wypych A, Rokicka-Milewska R, Siedlecki JA, Kulik J.
    Przegl Lek; 2004 Apr; 61 Suppl 2():62-6. PubMed ID: 15686049
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, Slater RM, von dem Borne AE, van der Schoot CE.
    Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
    [Abstract] [Full Text] [Related]

  • 25. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Król M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A.
    Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
    [Abstract] [Full Text] [Related]

  • 26. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, Brunet S, Tormo M, Fernández-Abellán P, Guàrdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Bermúdez A, Cladera A, Escoda L, García-Boyero R, Del Potro E, Bergua J, Amigo ML, Grande C, Rabuñal MJ, Hernández-Rivas JM, Feliu E.
    J Clin Oncol; 2014 May 20; 32(15):1595-604. PubMed ID: 24752047
    [Abstract] [Full Text] [Related]

  • 27. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
    Gandemer V, Pochon C, Oger E, Dalle JH, Michel G, Schmitt C, de Berranger E, Galambrun C, Cavé H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Méchinaud F, Rorhlich P, Lutz P, Demeocq F, Schneider P, Plantaz D, Poirée M, Bordigoni P.
    Br J Haematol; 2014 May 20; 165(3):392-401. PubMed ID: 24479958
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN, Savva NN, Fedasenka UU, Romancova AS, Krasko OV, Eckert C, von Stackelberg A, Aleinikova OV.
    Leuk Res; 2011 Oct 20; 35(10):1312-20. PubMed ID: 21596436
    [Abstract] [Full Text] [Related]

  • 30. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P, Mortuza FY, Hoffbrand AV, Foroni L.
    Haematologica; 2002 Nov 20; 87(11):1126-34. PubMed ID: 12414341
    [Abstract] [Full Text] [Related]

  • 31. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
    Attarbaschi A, Mann G, Dworzak M, Urban C, Fink FM, Dieckmann K, Riehm H, Gadner H, Austrian Cooperative Study Group.
    Wien Klin Wochenschr; 2002 Feb 28; 114(4):148-57. PubMed ID: 12060981
    [Abstract] [Full Text] [Related]

  • 32. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group.
    Br J Haematol; 2009 Aug 28; 146(3):292-9. PubMed ID: 19500099
    [Abstract] [Full Text] [Related]

  • 33. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X, Zou Y, Wang H, Chen X, Ruan M, Chen Y, Yang W, Guo Y, Liu T, Zhang L, Wang S, Zhang J, Liu F, Cai X, Qi B, Chang L, Zhu X.
    Zhonghua Er Ke Za Zhi; 2014 Jun 28; 52(6):449-54. PubMed ID: 25190166
    [Abstract] [Full Text] [Related]

  • 34. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E.
    N Engl J Med; 1998 Aug 27; 339(9):591-8. PubMed ID: 9718378
    [Abstract] [Full Text] [Related]

  • 35. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
    Coustan-Smith E, Gajjar A, Hijiya N, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Andreansky M, Hancock ML, Pui CH, Campana D.
    Leukemia; 2004 Mar 27; 18(3):499-504. PubMed ID: 14981525
    [Abstract] [Full Text] [Related]

  • 36. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S, Kim DW, Cho BS, Yoon JH, Shin SH, Yahng SA, Lee SE, Eom KS, Kim YJ, Chung NG, Kim HJ, Min CK, Lee JW, Min WS, Park CW.
    Leukemia; 2012 Nov 27; 26(11):2367-74. PubMed ID: 22705993
    [Abstract] [Full Text] [Related]

  • 37. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
    Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR, International BFM Study Group (I-BFM-SG).
    Leukemia; 2008 Apr 27; 22(4):771-82. PubMed ID: 18239620
    [Abstract] [Full Text] [Related]

  • 38. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
    Rivera GK, Zhou Y, Hancock ML, Gajjar A, Rubnitz J, Ribeiro RC, Sandlund JT, Hudson M, Relling M, Evans WE, Pui CH.
    Cancer; 2005 Jan 15; 103(2):368-76. PubMed ID: 15599932
    [Abstract] [Full Text] [Related]

  • 39. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C, Dini G, Locatelli F, Miniero R, Tamaro P.
    Haematologica; 2000 Nov 15; 85(11 Suppl):47-53. PubMed ID: 11268324
    [Abstract] [Full Text] [Related]

  • 40. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
    Laughton SJ, Ashton LJ, Kwan E, Norris MD, Haber M, Marshall GM.
    J Clin Oncol; 2005 Apr 01; 23(10):2264-71. PubMed ID: 15800317
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 46.